Additional analysis from the DELTA 2 trial concluded that twice-daily application of delgocitinib cream resulted in minimal systemic exposure, further supporting its safety profile.

Delgocitinib cream produced statistically significant improvements in both patient- and clinician-reported efficacy outcomes in adults with moderate to severe chronic hand eczema (CHE) compared to cream vehicle, according to results from the DELTA 2 trial presented at the European Academy of Dermatology and Venereology Congress in Berlin. 

Delgocitinib an investigational topical pan-Janus kinase (JAK)- inhibitor for the potential treatment of adults with moderate to severe CHE.

DELTA 2 was a randomized, double-blind, vehicle-controlled trial. Adults were randomized to either twice daily delgocitinib cream (n=314) or cream vehicle (n=159) for 16 weeks followed by a separate 36-week extension trial. The primary endpoint was the proportion of patients with moderate severe CHE who achieved an Investigator’s Global Assessment (IGA)-CHE score of 0 (clear) or 1 (almost clear: barely perceptible erythema only) with a ≥2 point improvement from baseline at Week 16. A significantly greater proportion of delgocitinib-treated patients, compared to cream vehicle, achieved this IGA-CHE improvement (29.1% vs. 6.9% to cream). 

The trial also achieved its key secondary endpoints at Week 16, including a significantly greater  proportion of delgocitinib-treated patients achieving a ≥75% improvement in the Hand Eczema Severity Index (HECSI-75) compared to cream vehicle (49.5% vs. 18.2%; p<0.001).1 All endpoints were consistent with those previously reported from the identically designed DELTA 1 study, whose key results are also being presented at EADV this year.

An additional analysis of DELTA 2 concluded that twice-daily application of delgocitinib cream in moderate to severe CHE resulted in minimal systemic exposure over 16 weeks, further  adults with supporting its safety profile.

Other delgocitinib cream presentations at EADV include an overview and validation of IGA-CHE and Hand Eczema Symptom Diary (HESD) as study endpoints in the DELTA 1, 2 and 3 trials,  a systematic literature review of existing randomized controlled trial evidence for the treatment of  moderate to severe CHE in adults, and a pooled analysis of the DELTA 1 and 2 trials examining the effect of delgocitinib cream on health-related quality of life.